NASDAQ:PTCT PTC Therapeutics (PTCT) Stock Price, News & Analysis $36.64 +0.48 (+1.33%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get PTC Therapeutics alerts: Email Address About PTC Therapeutics Stock (NASDAQ:PTCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PTC Therapeutics alerts:Sign Up Key Stats Today's Range$35.22▼$37.1750-Day Range$31.00▼$36.6452-Week Range$17.53▼$40.69Volume1.15 million shsAverage Volume854,676 shsMarket Capitalization$2.82 billionP/E RatioN/ADividend YieldN/APrice Target$37.64Consensus RatingHold Company OverviewPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More… Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on retiring any time soon... Every retirement dollar you have invested in paper assets will only continue to drop in value. We just released a Free Guide that reveals all the details.Click here to get the free Gold Guide now. PTC Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 68th PercentilePTC Therapeutics scored higher than 68% of companies evaluated by MarketBeat, and ranked 386th out of 1,006 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.2 / 5Analyst RatingHold Consensus RatingPTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 6 buy ratings, 6 hold ratings, and 3 sell ratings.Amount of Analyst CoveragePTC Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about PTC Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($5.09) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -4.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about PTC Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.32% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in PTC Therapeutics has recently decreased by 5.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.38 Percentage of Shares Shorted7.32% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in PTC Therapeutics has recently decreased by 5.38%, indicating that investor sentiment is improving significantly. News and Social Media1.8 / 5News Sentiment0.19 News SentimentPTC Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for PTC Therapeutics this week, compared to 4 articles on an average week. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $77,191.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of PTC Therapeutics is held by insiders.Read more about PTC Therapeutics' insider trading history. Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Stock News HeadlinesCantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)September 18 at 9:29 AM | markets.businessinsider.comPTC Therapeutics (NASDAQ:PTCT) Receives Overweight Rating from Cantor FitzgeraldSeptember 18 at 4:59 AM | americanbankingnews.comTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on retiring any time soon... Every retirement dollar you have invested in paper assets will only continue to drop in value. We just released a Free Guide that reveals all the details.September 20, 2024 | Gold Safe Exchange (Ad)PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 12, 2024 | prnewswire.comPTC Therapeutics to Participate at Upcoming Investor ConferencesAugust 28, 2024 | prnewswire.comUBS Upgrades PTC Therapeutics (PTCT)August 27, 2024 | msn.comPTC Therapeutics: Balancing Strong FY24 Guidance Against Regulatory UncertaintiesAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for PTC Therapeutics on Strong Q2 Performance and Promising PipelineAugust 9, 2024 | markets.businessinsider.comSee More Headlines PTCT Stock Analysis - Frequently Asked Questions How have PTCT shares performed this year? PTC Therapeutics' stock was trading at $27.56 at the beginning of the year. Since then, PTCT shares have increased by 32.9% and is now trading at $36.64. View the best growth stocks for 2024 here. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($1.16) EPS for the quarter, missing the consensus estimate of ($1.00) by $0.16. The biopharmaceutical company had revenue of $186.70 million for the quarter, compared to analyst estimates of $192.12 million. Who are PTC Therapeutics' major shareholders? PTC Therapeutics' top institutional shareholders include Armistice Capital LLC (9.05%), Cowen AND Company LLC (4.90%), Renaissance Technologies LLC (1.07%) and Cubist Systematic Strategies LLC (0.62%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Eric Pauwels, Neil Gregory Almstead, Lee Scott Golden, Pierre Gravier, Emily Luisa Hill, Christine Marie Utter, Allan Steven Jacobson, David P Southwell, Alethia Young, Emma Reeve and Stephanie Okey. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA) and Cisco Systems (CSCO). Company Calendar Last Earnings8/08/2024Today9/20/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Target$37.64 High Stock Price Target$64.00 Low Stock Price Target$25.00 Potential Upside/Downside+2.7%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($7.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-626,600,000.00 Net Margins-53.25% Pretax Margin-54.87% Return on EquityN/A Return on Assets-19.37% Debt Debt-to-Equity RatioN/A Current Ratio2.23 Quick Ratio2.17 Sales & Book Value Annual Sales$937.82 million Price / Sales3.01 Cash Flow$2.63 per share Price / Cash Flow13.94 Book Value($10.85) per share Price / Book-3.38Miscellaneous Outstanding Shares76,920,000Free Float72,479,000Market Cap$2.82 billion OptionableOptionable Beta0.64 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:PTCT) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.